Home Search
cbd - search results
If you're not happy with the results, please do another search
Ilesol Pharmaceuticals: First European cannabinoid à la carte company
Here, Ilesol Pharmaceuticals discuss how they became the first European cannabinoid company to unlock this sector of the market.
New study finds 40% of plant species are at risk of extinction
A new study highlights that 40% of plant species are at threatened with extinction due to the continued destruction of our natural world.
EUMCA: Medical cannabis and research collaboration after Brexit
Here, we talk to Professor Trevor Jones at the European Medical Cannabis Association (EUMCA) about storing CBD, clinical trials post-Brexit and the UK-US trade deal.
Ensuring a high and reproducible quality of medicinal cannabis
Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.
MHL Series B equity financing and global CPG partnerships
Here, we learn how Mile High Labs, a leading processor of hemp-derived cannabinoids, have raised Series B equity financing and are preparing for global CPG partnerships.
Stop drug testing and start impairment testing
A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.
Lifescience Legal Design
Here, Lifescience Legal Design discuss the legal status of CBD and hemp in the European Union.
Can lavender aid those who struggle with insomnia?
Dr Deborah Lee, Dr Fox Online Pharmacy, explores how aromatherapy is fast emerging as a form of alternative medicine for many health conditions, including insomnia.
Chronic pain diseases and medical cannabis
Janosch Kratz discusses the importance of medical cannabis for chronic pain diseases.
How are different types of medical cannabis working for different diseases?
Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.
How cannabinoids can be used as pain medicine
Dr Daniela Tonucci, a consultant for over 10 years, talks us through the use of cannabinoids as pain medicine.
The EUMCA: Pioneering access to medicinal cannabis
Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
Expanding the portfolio of rigorous cannabinoid research with new funding opportunities
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.
Attracting major investors: GreenLight on the international stage
In the last six months GreenLight Medicines has successfully out-licenced leads from its research, branching out internationally and attracting major investors.
The medical cannabis space: A successful targeted investment strategy
In this interview, David Engel from Full Moon Investments in the U.S., charts the firm’s successful targeted investment strategy – informed by industry-leading experience and expertise – including comments on the CBD hemp and medical cannabis space.
Essential oils as a potential modulator of the endocannabinoid system
Dr Christian Löfke, responsible for research and product development at BioBloom, walks us through the rudiments of essential oils as a potential modulator of the endocannabinoid system.
Cannabinoids in medicine part 5: Treating COVID-19
In this final article of a series of five, Oxford Cannabinoid Technologies will discuss their expertise on the use of cannabinoids in medicine when it comes to treating COVID-19.
Christian Hendriksen – MileHigh Labs
Christian Hendriksen is VP of International Expansion at Mile High Labs.
COVID-19: A moment for legalising medical cannabis?
Here, Josh Smith talks us through the current pandemic and the recent history underlying the fight for legalising medical cannabis.
Globally addressing polypharmacy and multimorbidities with computational techniques
Dr Juliana Bowles, School of Computer Science, University of St Andrews, discusses how to tackle polypharmacy and multimorbidities with computational techniques.